CME

Faculty: J.A. Randy Englert, MD, FACC

Faculty: Matthew Malachowski, Pharm. D., MHA

This MinuteCE program brings a practical, team-based approach to improving atherosclerotic cardiovascular disease (ASCVD) prevention. Featuring expert multidisciplinary insights from Joseph Englert, MD, and Matt Malachowski, PharmD, this series focuses on identifying high-risk and underserved patients, advancing LDL-C–centered treatment strategies, and sustaining long-term secondary prevention.

Across the program, faculty highlight guideline-aligned approaches to risk assessment, treatment intensification—including combination lipid-lowering therapy—and ongoing lipid monitoring. Emphasis is placed on coordinated, systems-based care strategies that support adherence, streamline workflows, and improve patient outcomes to help clinicians close care gaps one inning at a time.

Faculty: J.A. Randy Englert, MD, FACC

Faculty: Matthew Malachowski, Pharm. D., MHA

This MinuteCE program brings a practical, team-based approach to improving atherosclerotic cardiovascular disease (ASCVD) prevention. Featuring expert multidisciplinary insights from Joseph Englert, MD, and Matt Malachowski, PharmD, this series focuses on identifying high-risk and underserved patients, advancing LDL-C–centered treatment strategies, and sustaining long-term secondary prevention.

Across the program, faculty highlight guideline-aligned approaches to risk assessment, treatment intensification—including combination lipid-lowering therapy—and ongoing lipid monitoring. Emphasis is placed on coordinated, systems-based care strategies that support adherence, streamline workflows, and improve patient outcomes to help clinicians close care gaps one inning at a time.

Faculty: Aditya Bardia, MD, MPH, FASCO

Oral selective estrogen receptor degraders (SERDs) are rapidly reshaping the treatment landscape in breast cancer, offering targeted treatment approaches that have demonstrated improvements in progression-free survival and expanded options for patients with ER-positive/HER2-negative disease. Recent ASCO data highlighted the growing role of oral SERDs in optimizing treatment sequencing, addressing ESR1 mutations, and supporting personalized care across early-stage and metastatic settings. These therapies may also facilitate more convenient, patient-centered management while advancing precision medicine approaches in breast cancer care.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.50.

Faculty: Aditya Bardia, MD, MPH, FASCO

Oral selective estrogen receptor degraders (SERDs) are rapidly reshaping the treatment landscape in breast cancer, offering targeted treatment approaches that have demonstrated improvements in progression-free survival and expanded options for patients with ER-positive/HER2-negative disease. Recent ASCO data highlighted the growing role of oral SERDs in optimizing treatment sequencing, addressing ESR1 mutations, and supporting personalized care across early-stage and metastatic settings. These therapies may also facilitate more convenient, patient-centered management while advancing precision medicine approaches in breast cancer care.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.50.

Faculty: Erica L. Mayer, MD, MPH

Oral selective estrogen receptor degraders (SERDs) are rapidly reshaping the treatment landscape in breast cancer, offering targeted treatment approaches that have demonstrated improvements in progression-free survival and expanded options for patients with ER-positive/HER2-negative disease. Recent ASCO data highlighted the growing role of oral SERDs in optimizing treatment sequencing, addressing ESR1 mutations, and supporting personalized care across early-stage and metastatic settings. These therapies may also facilitate more convenient, patient-centered management while advancing precision medicine approaches in breast cancer care.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.50.

Faculty: Maria Fleseriu, MD, FACE

Faculty: Shlomo Melmed, MBChB

Faculty: Elise M. Brett, MD, FACE

This broadcast replay from AACE 2026 features an interactive, case-based Q-Challenge format focused on acromegaly. Participants engage with clinical scenarios designed to assess and reinforce diagnostic evaluation and treatment decision-making. The activity highlights key considerations in identifying acromegaly, interpreting clinical findings, and selecting appropriate management strategies based on patient presentation. Through guided questions and expert-informed discussion, learners gain insight into the real-world application of evidence-based approaches.

Host: Brett Bade, MD

Guest: Michael Gieske, MD

This episode focuses on improving lung cancer screening and early detection by helping primary care providers recognize eligible and high-risk patients, apply current screening guidelines, and engage patients in clear shared decision-making conversations. Speakers will explore why many patients who qualify for low-dose CT scan screening are still not screened. Learn practice strategies to help close preventable gaps in care, including identifying risk during routine visits, addressing patient concerns, ordering appropriate screening, and ensuring follow-up for findings such as pulmonary nodules.

Faculty: Florence Odufalu, MD

Faculty: Ugo Iroku, MD, MHS

This 13-episode MinuteCE program examines contemporary treatment selection in inflammatory bowel disease, with emphasis on aligning therapy choice with disease phenotype, severity, prognosis, treatment goals, safety considerations, and patient-specific factors. Episodes cover conventional agents, anti-TNF therapies, gut-selective anti-integrins, IL-12/23 and IL-23 pathway inhibitors, JAK inhibitors, and S1P modulators, with attention to practical positioning in ulcerative colitis and Crohn’s disease. The program also discusses treat-to-target care, including STRIDE/STRIDE-II principles, and uses case-based segments to examine how comorbidities, extraintestinal manifestations, prior treatment failure, infection risk, pregnancy planning, and guideline-based care inform individualized IBD management.

Faculty: Florence Odufalu, MD

Faculty: Ugo Iroku, MD, MHS

Faculty: Sharon Dudley-Brown, PhD, FNP-BC, FAAN, FAANP

This 13-episode MinuteCE program examines contemporary treatment selection in inflammatory bowel disease, with emphasis on aligning therapy choice with disease phenotype, severity, prognosis, treatment goals, safety considerations, and patient-specific factors. Episodes cover conventional agents, anti-TNF therapies, gut-selective anti-integrins, IL-12/23 and IL-23 pathway inhibitors, JAK inhibitors, and S1P modulators, with attention to practical positioning in ulcerative colitis and Crohn’s disease. The program also discusses treat-to-target care, including STRIDE/STRIDE-II principles, and uses case-based segments to examine how comorbidities, extraintestinal manifestations, prior treatment failure, infection risk, pregnancy planning, and guideline-based care inform individualized IBD management.

Faculty: Ugo Iroku, MD, MHS

Faculty: Michael Dolinger, MD, MBA

This 13-episode MinuteCE program examines contemporary treatment selection in inflammatory bowel disease, with emphasis on aligning therapy choice with disease phenotype, severity, prognosis, treatment goals, safety considerations, and patient-specific factors. Episodes cover conventional agents, anti-TNF therapies, gut-selective anti-integrins, IL-12/23 and IL-23 pathway inhibitors, JAK inhibitors, and S1P modulators, with attention to practical positioning in ulcerative colitis and Crohn’s disease. The program also discusses treat-to-target care, including STRIDE/STRIDE-II principles, and uses case-based segments to examine how comorbidities, extraintestinal manifestations, prior treatment failure, infection risk, pregnancy planning, and guideline-based care inform individualized IBD management.